Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MIF | P14174 | 11/20 | 1.00 |
| ▸ | MPI | P34949 | 6/20 | 0.65 |
| ▸ | PMM2 | O15305 | 5/20 | 0.65 |
| ▸ | KAT2B | Q92831 | 2/20 | 0.60 |
| ▸ | G6PD | P11413 | 1/20 | 0.48 |
| ▸ | PHOSPHO1 | Q8TCT1 | 4/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.47 |
| ▸ | MGLL | Q99685 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8370731 | 0.84 | MIF (0.75) | MIFMPIPMM2KAT2BG6PD | |
| SCHEMBL2757828 | 0.80 | MIF (0.74) | MIFMPIPMM2KAT2BG6PD | |
| SCHEMBL2538424 | 0.79 | MPI (1.00) | MIFMPIPMM2KAT2BG6PD | |
| SCHEMBL22092498 | 0.77 | MIF (1.00) | MIFMPIPMM2KAT2BG6PD | |
| SCHEMBL13086617 | 0.77 | MIF (1.00) | MIFMPIPMM2KAT2BG6PD | |
| SCHEMBL8371737 | 0.74 | MIF (0.59) | MIFMPIPMM2KAT2BG6PD | |
| SCHEMBL3949562 | 0.69 | MPI (0.53) | MIFMPIPMM2KAT2BG6PD | |
| SCHEMBL8370730 | 0.69 | PHOSPHO1 (0.57) | MIFMPIPMM2KAT2BG6PD | |
| SCHEMBL8369491 | 0.69 | MPI (0.57) | MIFMPIPMM2KAT2BG6PD | |
| SCHEMBL8373532 | 0.69 | MIF (0.74) | MIFMPIPMM2G6PDPHOSPHO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020123610-A1 | COMPOUNDS AND METHODS FOR TREATING COPD AND/OR LUNG FIBROSIS | YALE UNIVERSITY (US) | 2020-06-18 | — | — | WO | claimed |
| US-20200377457-A1 | MIF MODULATORS | UNIV YALE (US) | 2020-12-03 | — | — | US | disclosed |
| WO-2020123610-A1 | COMPOUNDS AND METHODS FOR TREATING COPD AND/OR LUNG FIBROSIS | YALE UNIVERSITY (US) | 2020-06-18 | — | — | WO | disclosed |
| WO-2020123610-A1 | COMPOUNDS AND METHODS FOR TREATING COPD AND/OR LUNG FIBROSIS | YALE UNIVERSITY (US) | 2020-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200377457-A1 | MIF MODULATORS | MIF, HMGB2, HMGB3 | MIF 1/4885MPI 102/4885PMM2 856/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.